drugset / Trial / NCT00290732
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Phase 1
Completed
20 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy in different ways, such as into the breast ducts, may kill more tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase I trial is studying the side effects and best dose of liposomal doxorubicin when given before mastectomy in treating women with invasive breast cancer.
Timeline
- Start
- 2005-11
- Primary completion
- 2011-05
- Completion
- 2011-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 1 mg | Other |
| Subject | Doxorubicin | Other / unclassified | 2 mg | Other |
| Subject | Doxorubicin | Other / unclassified | 5 mg | Other |
| Subject | Doxorubicin | Other / unclassified | 10 mg | Other |